Keltic Pharma Therapeutics
In 2019 Prof Andrew Tobin published validation of PfCLK3 as a target with breakthrough potential in the treatment of malaria. Successful drug development would provide a single medicine that is curative, transmission blocking and prophylactic.
7-day free trial · no credit card
Verified contacts
8
available on Kipplo
LinkedIn employees
7
11 to 50 range
Open roles
—
no listings
Distinct roles
7
indexed titles
Tech stack
0
tools in use
Monthly traffic
—
organic / mo
Sign up free to see all 8 verified contacts at Keltic Pharma Therapeutics
Free for 7 days · 50 credits · no card · only pay for verified records.
Decision-makers and verified team members
8 contacts with verified email or phone · masked until revealed.
- AJ
Andrew Jamieson
Chief Scientific Officer · Science
EmailPhone - AT
Andrew Tobin
Chief Executive Officer and Founder · General Business & Management
EmailPhone
Showing 2 of 8 verified contacts
Top roles at Keltic Pharma Therapeutics
7 distinct titles indexed · top 7 shown.
- 2peptide chemist
- 1chief executive officer and founder
- 1chief scientific officer
- 1parasitology research scientist
- 1research scientist
- 1scientist
- 1senior scientist - parasitologist
Sign up to unlock all 8 contacts at Keltic Pharma Therapeutics
Free for 7 days · 50 credits · no card · only pay for verified records.
Sign up to reveal 8 verified contacts at Keltic Pharma Therapeutics
7-day trial · no credit card · cancel anytime · only pay for verified records.
Trusted by sales, marketing, and GTM engineering teams.